[{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FUROSCIX\u00ae NDA Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FDA Acceptance of FUROSCIX\u00ae New Drug Application Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX\u00ae (furosemide) for subcutaneous administration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"scPharmaceuticals Announces Pricing of $50 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Resubmission of FUROSCIX New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. to Host FUROSCIX\u00ae (furosemide) 80mg\/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FDA Approval of FUROSCIX\u00ae (furosemide injection), the First and Only Self-Administered, Subcutaneous Loop Diuretic for the At-Home Treatment of Congestion in Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Congestion Due to Fluid Overload in Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Provides Furoscix (furosemide injection) Commercial Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX\u00ae (furosemide injection)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Furosemide for Injection in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg\/mL) Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals for Furosemide
TABLET;ORAL - 20MG, TABLET;ORAL - 40MG, TABLET;ORAL - 80MG, INJECTABLE;INJECTION - 10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Furoscix (furosemide injection) auto-injector is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lasix-Generic (furosemide) is a USFDA approved loop diuretic, which is indicated for the treatment of adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Furoscix (furosemide injection) is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
FUROSCIX® (furosemide injection) is a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
FUROSCIX® (furosemide injection) is a drug product indicated for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II/III chronic heart failure.
scPharmaceuticals plans to use funds, together with cash on-hand, to repay indebtedness under its existing loan and security agreement and to execute on the launch of FUROSCIX (furosemide), which received marketing approval from the U.S. FDA.
FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for treatment of congestion,demonstrated 99.6% bioavailability and 8-hour urine output of 2.7 L which was similar to subjects receiving intravenous furosemide.